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Aims: The aims of this study were to assess the outcomes of patients who underwent potentially curative
hepatic resection for hepatocellular carcinoma (HCC) in a background of non-cirrhotic/non-ﬁbrotic livers,
and to determine prognostic factors that inﬂuenced survival.
Methods: Over a 15-year period, all patients undergoing hepatectomy for HCC were identiﬁed. Collated
data included demographics, laboratory analysis, operative ﬁndings and histo-pathological data. Survival
differences between these factors following liver resection were determined.
Results: 57 patients were included with a median age of 70 years. The majority of patients underwent a
hemi-hepatectomy or more radical resection (n ¼ 37). Overall R0 resection rate was 90.4% (n ¼ 51). The
overall morbidity and mortality rates were 26.3% and 3.5%, respectively. The median follow-up period
was 28 months. The 1-, 3- and 5- year disease-free survival was 65.4%, 41.8% and 39.1%, and the overall
survival was 73.5%, 49.6% and 39.5%, respectively. AFP (p ¼ 0.039) was the only predictor of poorer
disease-free survival on univariate analysis. On multi-variable analysis, poorly differentiated tumour and
large tumour size were independent predictors of overall survival.
Conclusions: Liver resection is a feasible treatment option for HCC in non-cirrhotic/non-ﬁbrotic livers
with good survival outcome. Tumour size and differentiation are adverse predictors of outcome in these
patients.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth commonest malig-
nancy worldwide,1 and recent evidence suggests that its incidence
is on the rise in the Western World. Irrespective of aetiology, over
80% of HCC occur in patients with a background of liver cirrhosis.2
The therapies which are capable of providing potential long term
cure are hepatic resection and liver transplantation. Liverociety of Surgical Oncology,
iary Unit, Aintree University
pool L9 7AL, UK. Tel.: þ44 151
V.S. Yip), Graeme.poston@
ciates Ltd. Published by Elsevier Lttransplantation is regarded as the optimal treatment for selected
cirrhotic patients, as it treats both the malignancy and underlying
parenchymal disease. The Milan criteria and the University of Cal-
ifornia, San Francisco (UCSF) criteria are widely used for the se-
lection of patients for liver transplantation,3 as these criteria have
been shown to be associated with better overall survival.4e6
However, HCC arising from non-cirrhotic livers tend to have bet-
ter outcomes following liver resection as it is associated with a
lower recurrence rate compared to liver transplantation.7
The majority of published studies on the surgical management
of HCC are from the Far East and Africa due to the higher prevalence
of viral hepatitis B and C, which is associated with liver cirrhosis in
these geographical regions.8 These studies tend to analyse the
clinical outcome of both non-cirrhotic and cirrhotic livers as the
same entity.2,9e11 In comparison, there are currently fewer pub-
lished reports on HCC arising from non-cirrhotic livers in Westernd. All rights reserved.
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disease process of HCC arising within non-cirrhotic livers may be
different from that of the cirrhotic livers.16
The aim of this study was to assess the outcomes of patients
who underwent potentially curative hepatic resection for HCC in a
background of non-cirrhotic and non-ﬁbrotic livers. The secondary
aim included determining prognostic factors that inﬂuenced
survival.
2. Patients and methods
All patients with HCC undergoing hepatic resection with cura-
tive intent at our Hepatobiliary Unit during the 15-year period from
January 1996 to August 2011 were identiﬁed from a prospectively
maintained hepatobiliary database. Patients with ﬁnal histological
diagnosis of HCC and without liver ﬁbrosis and cirrhosis were
included in this study; whereas histo-pathological diagnosis of
ﬁbrolamellar HCC was excluded.
Preoperative evaluation
Collated data included patient demographics, laboratory ana-
lyses (<1 week prior liver resection), type of surgery, histopathol-
ogy analysis and clinical outcome. Pre-operative radiological
assessment included a computer tomography (CT) scan of the
thorax, abdomen and pelvis, and magnetic resonance imaging
(MRI) of the liver (from 2008). All patients were discussed in our
specialist multidisciplinary meeting that consisted of hepatobiliary
surgeons, hepatologist, oncologist, radiologist and pathologist prior
to surgery.
Surgical and post-operative details
Parenchymal transection was performed using the CaviePulse
Ultrasonic Surgical Aspirator (CUSA) or Kellyclasia. Intra-operative
ultrasound was performed to conﬁrm the ﬁndings of pre-
operative imaging and to assist in surgical planning. The number
of hepatic (Couinaud’s) segments17 resectedwas determined by the
procedure performed as stated in the Brisbane nomenclature.18
Type of surgical procedure was dependent on the resection of all
macroscopic disease and achieving a clear resection margin, while
preserving sufﬁcient remnant liver. The length of hospital stay,
post-operative complications and 30-day mortality were recorded.
ClavieneDindo classiﬁcation (Grade IeV) was used to quantify
post-operative complications.19
Histo-pathological analysis
The non-ﬁbrotic and non-cirrhotic status of the liver was
conﬁrmed by an independent pathologist (MT). The tumour dif-
ferentiation was graded as well, moderately and poorly differenti-
ated HCC. Largest diameter of the tumour (mm), capsular
involvement, micro- and/or macro vascular involvement, and
resection margin (mm) were also recorded. R0 resection was
deﬁned as no microscopic evidence of tumour at or within 1 mm of
the margin.
Follow-up protocol
Patients were followed up in specialist hepatobiliary clinics.
Following initial post-operative review at one month, all patients
were examined in the outpatient clinic at 3, 6, 12, 18 and 24months
and annually thereafter. At each clinic review, blood tests were
performed for liver function tests and a-fetoprotein (AFP) levels. All
patients had a minimum follow-up of 1 year following surgery.Patients underwent 6-monthly surveillance CT scan of the thorax,
abdomen and pelvis during the ﬁrst two post-operative years, fol-
lowed by annual CT scans thereafter. Liver MRI was used to char-
acterize suspicious hepatic lesions demonstrated on CT.
Over the past 6 years or so, with the increasing availability of
using Sorafenib for advanced HCC, patients with disease recurrence
after HCC resections were referred to oncologist for the consider-
ation of adjuvant chemotherapy.
Overall and disease-free survival data was recorded, with
disease-free survival deﬁned as the time from primary hepatic
resection to the ﬁrst documented disease recurrence on imaging or
death. Overall survival was deﬁned as the time interval between
the date of primary hepatic resection and the date of death or most
recent date of follow-up if the patient was still alive.
Statistical analysis
Categorical datawas presented as frequency and proportions (%)
and was analyzed using the Pearson’s chi-squared test or Fisher’s
exact test. Median and range were used to describe continuous
data. The KaplaneMeier method was used to assess the actuarial
survival and disease-free survival. Univariate analysis was per-
formed to assess for a signiﬁcant difference in clinico-pathological
characteristics that inﬂuenced disease recurrence and survival
following curative resection. Amultivariate analysis was performed
by Cox regression (Step-wise forward model) for variables signiﬁ-
cant on univariate analysis. All statistical analyses were performed
using the SigmaPlot v.12 for Windows (Systat, US) and statistical
signiﬁcance was taken at the 5% level.
3. Results
During the study period, 57 consecutive hepatectomies for non-
cirrhotic and non-ﬁbrotic HCC were identiﬁed. All patients were
Caucasian, and the majority of patients were male (n ¼ 33, 57.9%).
The median age was 70 years (range: 24e88 years). Demographics
and clinical factors are summarised in Table 1. None of the patients
underwent pre-operative liver biopsies.
The frequency of distribution of hepatectomies were segmental
resections (n ¼ 18), left hemi-hepatectomy (n ¼ 14), right hemi-
hepatectomy (n ¼ 12), extended right hemi-hepatectomy (n ¼ 8)
and extended left hemi-hepatectomy (n ¼ 3).
The overall R0 resection rate was 90.4% (n ¼ 51). Fifty (87.7%)
patients had a solitary tumour and evidence of micro-vascular in-
vasion was observed in 21 (36.8%) patients. Capsular involvement
was reported in 20 (35.1%) cases and mild to moderate steatosis
was observed in 20 (35.1%) cases. Tumour differentiationwerewell,
moderate and poor in 15 (26.3%), 29 (50.9%) and 13 (22.8%) cases,
respectively.
The overall morbidity rate was 26.3% (n ¼ 15), with Grade II
complications observed in 12 patients, followed by Grade V (n ¼ 2)
and Grade IVa (n ¼ 1). Twenty one post-operative complications
occurred in 15 patients. The 30-day mortality rate was 3.5% (n ¼ 2),
as a result of pseudomembranous colitis (n ¼ 1) and acute liver
failure (n ¼ 1).
Prognostic factors inﬂuencing survival outcome
During the study period, 31 (54.4%) patients died, of whom 24
(42.1%) patients had recurrent disease. Recurrent disease were
observed in the remnant liver (n ¼ 13), lung (n ¼ 1), para-aortic
lymphadenopathy (n ¼ 1) and widespread metastases (n ¼ 9).
The median follow-up period was 28 months (range: 12e178
months).
Table 1
Demographic, operative and histo-pathological data of patients in this study.
Demographic, operative and histo-pathological data (n ¼ 57)
Demographics
Age (years) 70 (22e88)
Male gender 33
Albumin (35e50 g/L) 41 (21e51)
Bilirubin (0e21 mmol/L) 10 (5e32)
Alkaline phosphatase (30e130 m/L) 130 (48e1169)
Neutrophils (1.9e8.0  109/L) 4.95 (2.23e14.52)
Lymphocytes (0.9e4.5  109/L) 1.66 (0.67e12.37)
Neutrophils/lymphocytes ratio 2.59 (0.35e10.65)
a-fetoproteina (0e15 im/ml) 7.50 (1e57,181)
Operative data
Major resection (hemi-hepatectomy or more) 37
Length of stay (days) 10 (4e42)
Blood transfusion (units) 0 (0e8)
Histo-pathology data
Tumour size 102 (14e235)
>1 nodule 10
Poorly differentiation 13
Resection margin (mm) 5.00 (0e80)
Micro- and macro- vascular invasion 21
Capsular invasion 21
Portal vein invasion 6
Presence of steatosisb 11
a Results were available for 32 patients only.
b Results were available for 22 patients only.
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Fig. 1. Overall survival of patients based on tumour differentiation.
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39.1%, respectively. AFP (p¼ 0.039) was the only predictor of poorer
disease-free survival on univariate analysis (Table 2).
The 1-, 3-, and 5- year overall survival was 73.5%, 49.6% and
39.5%, respectively. Tumour size (p ¼ 0.039) and tumour differen-
tiation (p ¼ 0.020) were variables associated with poorer overall
survival on univariate analysis (Fig. 1). On multi-variable analysis,
poorly differentiated tumour and large tumour size were inde-
pendent predictors of overall survival (Table 3).Table 2
Uni-variate analysis of overall and disease-free survival.
Survival data p-Value
Disease-free
survival
Overall
survival
Demographics
Age (years) 0.487 0.140
Male gender 0.241 0.081
Albumin > 50 g/L 0.832 0.876
Bilirubin > 21 mmol/L 0.106 0.359
Alkaline phosphatase > 130 iU/L 0.344 0.587
Neutrophils > 8.0  109/L 0.568 0.869
Lymphocytes > 4.5  109/L) 0.076 0.142
Neutrophils/lymphocytes ratio 0.079 0.335
a-fetoproteina 0.039 0.425
Operative data
Major resection (hemi-hepatectomy or more) 0.386 0.202
Blood transfusion 0.982 0.368
Histo-pathology data
Tumour size 0.073 0.039
>1 nodule 0.350 0.546
Poorly differentiated tumour 0.804 0.020
Resection margin (mm) 0.462 0.401
Micro- and macro- vascular invasion 0.201 0.115
Capsular invasion 0.823 0.678
Portal vein invasion 0.472 0.778
Presence of steatosisb 0.526 0.810
a Results were available for 32 patients only.
b Results were available for 22 patients only.4. Discussion
Advances in diagnostic, anaesthetic, and surgical techniques
have led to signiﬁcant reductions in perioperative morbidity and
mortality such that resection is now an important arm in the
multidisciplinary approach to HCC. Although the outcome
following liver resection for HCC is inﬂuenced by background
cirrhosis, recent studies have focused on the outcomes of liver
resection for HCC arising in non-cirrhotic livers. The larger series of
HCC resections from non-cirrhotic patients are from the Far East,
mostly due to endemic viral hepatitis B.20e22 Recently, there have
been reports from Western centres on this speciﬁc type of dis-
ease,23,24 and 20e50% of patients undergoing liver resection for
HCC did not have underlying cirrhosis.25,26
With respect to post-operative outcomes, previous studies have
reported morbidity and mortality rates ranging from 8 to 40% and
0e6%, respectively following hepatectomy for patients with HCC in
non-cirrhotic livers.12,15,20,27,28 The present series reported similarTable 3
Multi-variate analysis of variables inﬂuencing overall survival.
Clinical variables for
overall survival
Multi-variate
analysis
Risk
ratio
Conﬁdence
interval
Tumour size 0.032 1.008 1.001e1.015
Tumour differentiationa 0.007 0.336 0.153e0.738
a Tumour differentiations (well and moderate versus poor) were analysed as
categorical co-variate.
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undergoing a hemi-hepatectomy or more, suggesting that major
liver resection is safe for patients with this sub-type of HCC.
The current literature observes a 5-year survival of 25e81%
following liver resection for patients with HCC,12,14,15,20,21,29e31
irrespective of the status of the background liver parenchyma. In
addition, the overall survival tends to be worse for patients with
HCC arising from cirrhotic livers.12,27,31 The present series reported
survival outcomes similar to the current available published
literature.
In the presence series, an AFP level was identiﬁed as a signiﬁcant
risk factor for disease-free survival. Despite being frequently
identiﬁed as an independent prognostic indicator in multi-variate
analyses for overall survival32e34 and disease-free survival,32,35,36
the relevance of AFP has not been addressed speciﬁcally in rela-
tion to resection. It is probably a reﬂection of tumour biology and
thus, a surrogate marker for size or stage of the tumour.
Following multi-variate analysis, tumour size and tumour dif-
ferentiation were independent prognostic factors inﬂuencing
overall survival in this cohort of patients. Tumour size is well-
accepted as an important prognostic indicator on multi-variate
analysis for overall survival, but not disease-free survival.37e39
Whilst there is little doubt that the results are superior for small
tumours (<5 cm), several studies have now indicated that resection
for larger tumours (>5 cm),40,41 and “giant” tumours (>10 cm)
which would also be exempt from transplantation, are
encouraging.34
A high tumour grade has been shown to be associated with a
poorer overall36,42,43 and disease-free44 survival. The tumour grade
as assessed by an EdmonsoneSteiner score of pleomorphism
indicated that patients with low grade tumours had a median
survival of 4.9 years which was signiﬁcantly better than the 3.5
years seen for those with higher grade HCCs.42 Likewise, Sasaki and
colleagues reported a 40% disease-free survival for patients with an
EdmonsoneSteiner grade 1e2 but only 24% for those with grades
3e4.44 In this cohort, a signiﬁcantly poorer outcome in overall
survival was observed in poorly differentiated HCC compared to
well or moderate differentiated HCC. More than 80% of patients
died within 36 months in the poorly differentiated group,
compared to 50% in the moderate and well differentiated groups.
Similar observations have been reported.14,23,30 Previous data have
suggested that vascular invasion and presence of tumour at the
resection margin were signiﬁcant histological predictors of disease
recurrence. Lang et al. reported the association of micro-vascular
invasion in moderately and poorly differentiated non-cirrhotic
HCC tumours.45 This ﬁnding might offer an explanation regarding
the aggressiveness of the disease process, and also the risk of extra-
hepatic recurrence. Nevertheless, this feature was not observed in
the present cohort of patients.
There is no standardised adjuvant chemotherapy for this sub-
group of patients with HCC, and further research is required to
elucidate this. Poor prognostic markers such as elevated AFP and
tumour differentiation could be used in selecting patients for
adjuvant therapy. Although other variables such as R1 resection,
multiple tumours and vascular invasion14,23 were not identiﬁed as
signiﬁcant prognostic factors, these factors should not be neglected
when selecting patients for clinical trials.
The small sample size of the present study may be the limiting
factor that other clinico-pathological factors did not have a signif-
icant impact on outcome following resection. Furthermore, one of
the main differences between previous studies and the present
series is that all patients with any degree of liver ﬁbrosis and
cirrhosis were excluded. This is a reﬂection of the rare entity of this
disease (HCC arising in non-cirrhotic livers) in the Western popu-
lation.23,24 Furthermore, most published data tend to incorporatepatients with minimally ﬁbrotic or cirrhotic livers, and therefore
report a higher total number of patients.31 Since the histopatho-
logical features of tumour size and differentiation in this group of
patients have a higher risk of recurrence or poorer prognosis, they
may beneﬁt from more intensive post-operative follow-up and
possible adjuvant therapy.
The other limitation is the unavailability of viral hepatitis status.
HBV is not epidemic in the UK. The prevalence of HBV in the healthy
white UK ethnic population is 3.63%, and 0.37% for past-cleared and
current hepatitis B infection.46 During the study period, the prev-
alence of HCV in the UK was 0.06%. Hence, it is unlikely that any
patients in this series were infected with viral hepatitis.
In conclusion, liver resection is a feasible treatment option for
HCC in non-cirrhotic and non-ﬁbrotic livers. Tumour characteristics
such as tumour size and differentiation have been identiﬁed as
adverse predictors of outcome in patients undergoing potentially
curative resection for this sub-type of HCC. Patients with these
histopathological features may be considered for additional ther-
apies following resection.
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